PCV13 Vaccine for Solid Organ Transplant Recipients

N/A

Waitlist Available

Led By Jaime G Deville, MD, FAAP

Research Sponsored by University of California, Los Angeles

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Have received a solid organ transplantation requiring ongoing immunosuppression

Have received at least 3 doses of an approved PCV7 and/or PCV13 vaccine series

Timeline

Screening 3 weeks

Treatment Varies

Follow Up measured at different time points until 240 weeks post pcv 13 booster dose

Awards & highlights

Study Summary

This trial will test a vaccine to see if it's safe & effective for children with organ transplants.

Who is the study for?

This trial is for children aged 12 to 59 months who have had a solid organ transplant and are on immunosuppressive drugs (excluding certain non-steroidal agents). They must have completed at least three doses of an approved pneumococcal vaccine series, can complete the study, and have parental consent. Children with immune diseases, bleeding disorders, recent vaccinations, or severe reactions to vaccines cannot participate.Check my eligibility

What is being tested?

The trial is testing the safety and effectiveness over time of the Pneumococcal Conjugate Vaccine 13 (PCV13) in young children who have received solid organ transplants. The goal is to see how well these children's bodies respond to the vaccine given their unique health situation.See study design

What are the potential side effects?

While not specified here, common side effects of PCV13 in transplant recipients may include pain at injection site, fever, fatigue, headache and muscle pain. Serious allergic reactions are rare but possible.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have had an organ transplant and am on medication to prevent rejection.

Select...

I have received at least 3 doses of the pneumonia vaccine.

Select...

My child is between 1 and 4 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ measured at different time points until 240 weeks post pcv 13 booster dose

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~measured at different time points until 240 weeks post pcv 13 booster dose

This trial's timeline: 3 weeks for screening, Varies for treatment, and measured at different time points until 240 weeks post pcv 13 booster dose for reporting.